Previous 10 | Next 10 |
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 16:42:19 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences reports Q4 results Solid Biosciences signs agreement with Armatus Bio for AAV-SLB101 Seeking Alpha’s Quant Ratin...
2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...
2024-03-13 08:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystr...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-08 09:23:14 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio stock jumps 13% on positive data for DMD drug Regenxbio Q4 2023 Earnings Preview...
2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...
2024-03-04 09:47:00 ET On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process. Argyrides' calculation is likely that Sarepta will successful...
– Applications for the 2024-2025 academic year will be accepted until May 13, 2024 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta T...
2024-02-29 00:00:16 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q4 2023 Earnings Call Feb 28, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Tr...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...
2024-06-13 15:15:01 ET Citigroup analyst issues BUY recommendation for SRPT on June 13, 2024 01:18PM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.865 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-06-13 11:00:06 ET Brian Skorney from Robert W. Baird issued a price target of $170.00 for SRPT on 2024-06-13 10:14:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $124. The overall price target consensus is at $...